Recommended Citation
Ahluwalia MS, Chao ST, Parsons MW, Suh JH, Wang D, Mikkelsen T, Brewer CJ, Smolenski KN, Schilero C, Rump M, Elson P, Angelov L, Barnett GH, Vogelbaum MA, Weil RJ, and Peereboom DM. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases. J Neurooncol 2015; 124(3):485-491.
Document Type
Article
Publication Date
9-1-2015
Publication Title
Journal of neuro-oncology
Abstract
Patients with 1-3 brain metastases (BM) often receive sterotactic radiosurgery (SRS) without whole brain radiotherapy (WBRT). SRS without WBRT carries a high rate of relapse in the central nervous system (CNS). This trial used sunitinib as an alternative to WBRT for post-SRS adjuvant therapy. Eligible patients with 1-3 newly diagnosed BM, RTOG RPA class 1-2, received sunitinib after SRS. Patients with controlled systemic disease were allowed to continue chemotherapy for their primary disease according to a list of published regimens (therapy + sunitinib) included in the protocol. Patients received sunitinib 37.5 or 50 mg/days 1-28 every 42 days until CNS progression. Neuropsychological testing and MRIs were obtained every two cycles. The primary endpoint was the rate of CNS progression at 6 months (PFS6) after SRS. Fourteen patients with a median age of 59 years were enrolled. Primary cancers included lung 43 %, breast 21 %, melanoma 14 %. Toxicity included grade 3 or higher fatigue in five patients and neutropenia in two patients. The CNS PFS6 and PFS12 were 43 ± 14 and 34 ± 14 %, respectively. Of the ten patients who completed >1 neurocognitive assessment, none showed cognitive decline. Sunitinib after SRS for 1-3 BM was well tolerated with a PFS6 of 43 %. The prevention of progressive brain metastasis after SRS requires the incorporation of chemotherapy regimens to control the patient's primary disease. Future trials should continue to explore the paradigm of secondary chemoprevention of BM after definitive local therapy.
Medical Subject Headings
Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cognition Disorders; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neuropsychological Tests; Pyrroles; Radiosurgery; Salvage Therapy; Sunitinib; Treatment Outcome
PubMed ID
26245136
Volume
124
Issue
3
First Page
485
Last Page
491
